Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tetratherix Limited ( (AU:TTX) ) has shared an update.
Tetratherix Limited has entered into a strategic licensing agreement with Bio Optix Inc. to develop and commercialize an ophthalmic viscoelastic device, aiming to disrupt the $700 million global OVD market. This partnership will see Tetratherix manufacturing the products in Australia and becoming a minority shareholder in Bio Optix. Additionally, Tetratherix’s joint venture, Tutelix, is progressing with FDA pre-submission for its prostate spacer product, targeting clearance by FY28. The company also successfully raised $25 million through its ASX listing, positioning itself for accelerated growth and expansion, supported by a strong cash position and zero debt.
The most recent analyst rating on (AU:TTX) stock is a Buy with a A$5.72 price target. To see the full list of analyst forecasts on Tetratherix Limited stock, see the AU:TTX Stock Forecast page.
More about Tetratherix Limited
Tetratherix Limited operates in the medical technology industry, focusing on developing advanced polymer-based solutions. The company is known for its proprietary Tetramatrix platform and is engaged in creating products like ophthalmic viscoelastic devices and tissue spacers. Tetratherix is positioned for global expansion with its recent listing on the ASX.
Average Trading Volume: 109,287
Learn more about TTX stock on TipRanks’ Stock Analysis page.